Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 1997

View Archived Issues

Encouraging phase I results for porcine neural cell product

Lysostaphin found superior to vancomycin in treating MRSA

SNX-111 clinical data presented at international pain meeting

U.S. patent issued for Cell Genesys CNS gene therapy

IL-2 + IFN-alpha in phase II for renal cell carcinoma

Protective effects of Bayer's LTD4 antagonist demonstrated in asthmatic subjects

Antibacterial mutilin derivatives

Cytokine inhibitors presented by SKB

Peptidoleukotrienes and TxA2 both implicated in cough variant asthma

New bradykinin antagonists from Sanofi

Antileukotriene effects described for ebastine

HIV protease inhibitors under development at Vertex

Gene therapy for AIDS in development at Theratechnologies

Pharmacia & Upjohn continues SAR studies on oxazolidinones

New treatment for ISH evaluated in humans

Single- and multiple-dose clinical studies reported for SL-91.0102

New agents for NIDDM presented by Pharmacia & Upjohn

A-5021: a potent and selective antiherpesvirus agent from Ajinomoto

Launch announced for new ulcerative colitis Rx

Third pivotal trial of VX-478 commences

RPR seeks U.K. approval for Synercid

Matrix announces restructuring to focus on oncology products

Interstim approved for marketing in U.S.

Phase I/II data on MEDI-493 presented at ICAAC

Xoma's XMP peptides display antifungal activity

Preclinical pharmacokinetic/efficacy data on MiKasome presented at ICAAC

ABT-606: a new orally active diester prodrug of H2G

Collaborators demonstrate protection against HSV with Cel-Sci vaccine

Camptosar available in Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...